Varicella Clinical Trials

98 clinical trials for Varicella across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase 3a, open-label, randomized, controlled study to evaluate the immunogenicity and safety of intramuscular administration of an investigational varicella vaccine and Priorix compared with subcutaneous administration of Varivax and Priorix, when given as a first dose to healthy children 12 to 15 months of age — RECRUITING · PHASE3
• A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years — RECRUITING · PHASE3
• Second Dose of Varicella Vaccine in Healthy Children — RECRUITING · PHASE3
• Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective — RECRUITING
• An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine — RECRUITING · PHASE4
• An Immunity Persistence Study of Live Attenuated Varicella Vaccine — RECRUITING · PHASE4
• Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old — RECRUITING · PHASE3
• Pediatric and Ambulatory Research in Infectious Diseases — RECRUITING
• Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination — RECRUITING · PHASE2
• A Phase 3a, observer-blind, randomized, controlled study to evaluate the safety of an investigational varicella vaccine compared with Varivax, administered as a first dose to healthy children 12 to 15 months of age. — TERMINATED · PHASE3
• A Phase 3a, observer-blind, randomized, controlled study to demonstrate lot-to-lot consistency and evaluate the immunogenicity and safety of an investigational varicella vaccine compared with Varivax, administered as a first dose to healthy children 12 to 15 months of age. — TERMINATED · PHASE3
• A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age — NOT_YET_RECRUITING · PHASE3
• SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years — NOT_YET_RECRUITING · PHASE3
• Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children — NOT_YET_RECRUITING · PHASE3
• A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared with Varivax, When Given as a Second Dose to Healthy Children, 3 Months after the Administration of a First Dose at 12 to 15 Months of age — OTHER · PHASE3
• Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion) — COMPLETED · PHASE4
• Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine — NOT_YET_RECRUITING · PHASE4
• Correlation of Protection Against Varicella in an Exploratory Study — NOT_YET_RECRUITING
• Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines — COMPLETED · PHASE3
• A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy — OTHER · PHASE1
• Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old — COMPLETED · PHASE3
• Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines — OTHER · PHASE4
• A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age — OTHER · PHASE3
• A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine — ACTIVE_NOT_RECRUITING · PHASE3
• Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province — OTHER · PHASE4
• Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus — OTHER · PHASE4
• A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine — COMPLETED · PHASE4
• Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV — COMPLETED · PHASE3
• An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization — COMPLETED · PHASE3
• Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011) — COMPLETED · PHASE3
• Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058) — COMPLETED · PHASE3
• Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) — COMPLETED · PHASE3
• Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients — OTHER · PHASE2
• Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine — OTHER · PHASE4
• Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) — COMPLETED · PHASE3
• Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds — COMPLETED · PHASE2
• Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox — COMPLETED · PHASE3
• Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age — COMPLETED · PHASE3
• Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients — COMPLETED · PHASE3
• Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056) — COMPLETED · PHASE3
• Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM). — COMPLETED · PHASE2
• Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) — COMPLETED · PHASE3
• Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063) — COMPLETED · PHASE3
• Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age — COMPLETED · PHASE2
• Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children — COMPLETED · PHASE3
• ProQuad® Intramuscular vs Subcutaneous — COMPLETED · PHASE3
• A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine — COMPLETED · PHASE3
• Study of Two Formulations of GSK Biologicals' Varicella Vaccine — COMPLETED · PHASE2
• Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM — COMPLETED · PHASE3
• Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 — COMPLETED · PHASE3

Refine this search